| scholarly article | Q13442814 |
| P50 | author | Theodoros Kelesidis | Q37830063 |
| P2093 | author name string | Charalabos Pothoulakis | |
| P2860 | cites work | Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study | Q83006425 |
| Clinical efficacy of Saccharomyces boulardii and metronidazole compared to metronidazole alone in children with acute bloody diarrhea caused by amebiasis: a prospective, randomized, open label study | Q83941010 | ||
| Probiotic gastrointestinal allergic reaction caused by Saccharomyces boulardii | Q84369779 | ||
| Saccharomyces boulardii for treating acute gastroenteritis in children: updated meta-analysis of randomized controlled trials | Q84643983 | ||
| Application of the Colon-Simulation Technique for Studying the Effects of Saccharomyces boulardii on Basic Parameters of Porcine Cecal Microbial Metabolism Disturbed by Clindamycin | Q61908139 | ||
| Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventative agent in gnotobiotic mice | Q68003464 | ||
| Prevention of Clostridium difficile-induced experimental pseudomembranous colitis by Saccharomyces boulardii: a scanning electron microscopic and microbiological study | Q68533623 | ||
| Immunopharmacological effects of Saccharomyces boulardii in healthy human volunteers | Q69570230 | ||
| Influence of Saccharomyces boulardii on jejunal secretion in rats induced by cholera toxin | Q70029580 | ||
| Prevention of diarrhea administering Saccharomyces boulardii during continuous enteral feeding | Q70151156 | ||
| [Efficacy of Saccharomyces boulardii in the treatment of diarrhea in AIDS] | Q70185665 | ||
| Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum | Q70634956 | ||
| Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea--a pilot study | Q70641473 | ||
| Immunological and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers | Q71482489 | ||
| Inhibitory activity of saccharomyces yeasts on the adhesion of Entamoeba histolytica trophozoites to human erythrocytes in vitro | Q72352548 | ||
| Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers | Q72729258 | ||
| The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii | Q73118857 | ||
| Probiotics and gastrointestinal health | Q73351176 | ||
| Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea | Q73523895 | ||
| Effect of Lactobacillus strains and Saccharomyces boulardii on persistent diarrhea in children | Q79098908 | ||
| Saccharomyces boulardii and infection due to Giardia lamblia | Q79785370 | ||
| Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo-controlled study | Q79788376 | ||
| Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study | Q80650357 | ||
| European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe | Q81227501 | ||
| Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: Influence of Saccharomyces boulardii | Q81357142 | ||
| Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota | Q81402999 | ||
| Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea | Q81501084 | ||
| Influence of pH conditions on the viability of Saccharomyces boulardii yeast | Q81997160 | ||
| Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression | Q82789415 | ||
| Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells | Q24545538 | ||
| Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa | Q24548845 | ||
| Systematic review and meta-analysis of Saccharomyces boulardii in adult patients | Q24621081 | ||
| Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation | Q24654180 | ||
| Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations | Q24679315 | ||
| Saccharomyces boulardii improves intestinal cell restitution through activation of the α2β1 integrin collagen receptor | Q27348685 | ||
| Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii | Q28140653 | ||
| Saccharomyces boulardii in maintenance treatment of Crohn's disease | Q28144634 | ||
| A pilot trial of Saccharomyces boulardii in ulcerative colitis | Q28184581 | ||
| Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial | Q28237525 | ||
| Effects of Saccharomyces boulardii in children with acute diarrhoea | Q28247423 | ||
| A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease | Q28254686 | ||
| Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii | Q28276207 | ||
| Meta-analysis of probiotics for the prevention of traveler's diarrhea | Q28288124 | ||
| Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii | Q28289811 | ||
| Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection | Q28294880 | ||
| A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life | Q28304959 | ||
| Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines | Q28305169 | ||
| Premature stimulation of rat sucrase-isomaltase (SI) by exogenous insulin and the analog B-Asp10 is regulated by a receptor-mediated signal triggering SI gene transcription | Q28574939 | ||
| Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment | Q29042197 | ||
| Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children | Q30829512 | ||
| Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea | Q33222511 | ||
| Effective prophylaxis against rotavirus diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies | Q33300590 | ||
| Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study | Q33426019 | ||
| Possible role of catheters in Saccharomyces boulardii fungemia | Q33856125 | ||
| Recommendations for probiotic use--2008. | Q34012172 | ||
| A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children | Q34013199 | ||
| Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea | Q34017677 | ||
| Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). | Q34105840 | ||
| Saccharomyces boulardii induced sepsis: successful therapy with voriconazole after treatment failure with fluconazole | Q34402342 | ||
| Clinical practice. Antibiotic-associated diarrhea | Q34512995 | ||
| Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease | Q34517039 | ||
| Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. | Q34574132 | ||
| The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea | Q46207994 | ||
| Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study | Q46478462 | ||
| The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. | Q46494110 | ||
| Saccharomyces boulardii activates expression of peroxisome proliferator-activated receptor-gamma in HT-29 cells | Q46502993 | ||
| Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission | Q46515415 | ||
| Culture-dependent and culture-independent qualitative analysis of probiotic products claimed to contain bifidobacteria | Q46578797 | ||
| Inducible nitric oxide synthase involvement in the mechanism of action of Saccharomyces boulardii in castor oil-induced diarrhoea in rats | Q46614789 | ||
| Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication | Q46807963 | ||
| Saccharomyces boulardii ameliorates Citrobacter rodentium-induced colitis through actions on bacterial virulence factors. | Q46886597 | ||
| Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori | Q46899932 | ||
| Formulations for protecting the probiotic Saccharomyces boulardii from degradation in acidic condition | Q47946605 | ||
| Treatment of irritable bowel syndrome with Saccharomyces boulardii | Q48674668 | ||
| Effects of yeast probiotic formulation on viability, revival and protection against infection with Salmonella enterica ssp. enterica serovar Typhimurium in mice. | Q50052944 | ||
| Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella flexneri in conventional and gnotobiotic mice | Q50137792 | ||
| Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. | Q51743963 | ||
| Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. | Q54048773 | ||
| Effects of Saccharomyces boulardii on cytokine secretion from intraepithelial lymphocytes infected by Escherichia coli and Candida albicans. | Q54419605 | ||
| Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation. | Q54465441 | ||
| Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. | Q54572654 | ||
| Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed Saccharomyces boulardii | Q57121182 | ||
| Saccharomyces boulardiistimulates sIgA production and the phagocytic system of gnotobiotic mice | Q58227658 | ||
| Preventive effects of different probiotic formulations on travelers' diarrhea model in wistar rats : preventive effects of probiotics on TD. | Q34607596 | ||
| Experimental effects of Saccharomyces boulardii on diarrheal pathogens | Q34688679 | ||
| Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. | Q35532152 | ||
| Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events | Q35540167 | ||
| Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition | Q35621330 | ||
| Regulatory Oversight and Safety of Probiotic Use | Q35804961 | ||
| Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy | Q36481501 | ||
| Probiotics and the gut microbiota in intestinal health and disease | Q36567134 | ||
| Review article: yeast as probiotics -- Saccharomyces boulardii | Q36927633 | ||
| Meta-analysis of probiotics for the treatment of irritable bowel syndrome | Q37156630 | ||
| Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment | Q37177507 | ||
| Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives | Q37182888 | ||
| Saccharomyces boulardii effects on gastrointestinal diseases | Q37264160 | ||
| Saccharomyces boulardii in childhood | Q37355090 | ||
| Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii | Q37586528 | ||
| Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials | Q37678738 | ||
| Clinical utility of probiotics in inflammatory bowel disease. | Q37880028 | ||
| Screening of yeasts as probiotic based on capacities to colonize the gastrointestinal tract and to protect against enteropathogen challenge in mice. | Q39219877 | ||
| Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice | Q39519683 | ||
| Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells | Q39536940 | ||
| Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae. | Q39559926 | ||
| Enterohemorrhagic Escherichia coli infection induces interleukin-8 production via activation of mitogen-activated protein kinases and the transcription factors NF-kappaB and AP-1 in T84 cells | Q39654974 | ||
| Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii | Q39849111 | ||
| Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis | Q40260363 | ||
| Enteropathogenic Escherichia coli decreases the transepithelial electrical resistance of polarized epithelial monolayers. | Q40267720 | ||
| Saccharomyces boulardii prevents TNF-alpha-induced apoptosis in EHEC-infected T84 cells. | Q40314726 | ||
| Efficacy of saccharomyces boulardii with antibiotics in acute amoebiasis | Q40552298 | ||
| Evaluation of deficiencies in labeling of commercial probiotics | Q40564288 | ||
| Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial | Q40651311 | ||
| Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3',5'-cyclic monophosphate induction in intestinal cells. | Q41496914 | ||
| Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats | Q41765328 | ||
| The effects of Saccharomyces boulardii on bacterial translocation in rats with obstructive jaundice | Q42096451 | ||
| Recent advances in Saccharomyces boulardii research | Q42871284 | ||
| Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis | Q43183345 | ||
| Unraveling the causes of negative studies: a case of S boulardii for the prevention of antibiotic-associated diarrhea | Q43287412 | ||
| Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients | Q43678916 | ||
| Saccharomyces boulardii enhances N-terminal peptide hydrolysis in suckling rat small intestine by endoluminal release of a zinc-binding metalloprotease | Q43937317 | ||
| Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii | Q44032825 | ||
| Disposition kinetics of Saccharomyces boulardii in man and rat. | Q44265947 | ||
| Effects of antibiotics and Saccharomyces boulardii on bacterial translocation in burn injury | Q44785785 | ||
| Rapid determination of the bacterial composition of commercial probiotic products by terminal restriction fragment length polymorphism analysis | Q46202435 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Saccharomyces boulardii | Q135368 |
| probiotics | Q1816730 | ||
| P304 | page(s) | 111-125 | |
| P577 | publication date | 2012-03-01 | |
| P1433 | published in | Therapeutic Advances in Gastroenterology | Q21042423 |
| P1476 | title | Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders | |
| P478 | volume | 5 |
| Q35164905 | A review of the economics of treating Clostridium difficile infection |
| Q38124613 | Animal vaccines based on orally presented yeast recombinants |
| Q36256310 | Antimicrobial and antioxidant activities of Saccharomyces cerevisiae IFST062013, a potential probiotic |
| Q46456925 | Antioxidant properties and global metabolite screening of the probiotic yeast Saccharomyces cerevisiae var. boulardii |
| Q37100469 | Blastocystis: Consensus of treatment and controversies |
| Q49964363 | Cancer Chemopreventive, Antiproliferative, and Superoxide Anion Scavenging Properties of Kluyveromyces marxianus and Saccharomyces cerevisiae var. boulardii Cell Wall Components |
| Q37676927 | Catheter-related Saccharomyces cerevisiae Fungemia Following Saccharomyces boulardii Probiotic Treatment: In a child in intensive care unit and review of the literature |
| Q52759357 | Commensal Fungi in Health and Disease. |
| Q36327809 | Comparison of Two Forms of Loperamide-Simeticone and a Probiotic Yeast (Saccharomyces boulardii) in the Treatment of Acute Diarrhoea in Adults: A Randomised Non-Inferiority Clinical Trial |
| Q34554028 | Complete genome sequence and comparative genomics of the probiotic yeast Saccharomyces boulardii |
| Q37255990 | Dynamic In Vitro Models of the Human Gastrointestinal Tract as Relevant Tools to Assess the Survival of Probiotic Strains and Their Interactions with Gut Microbiota |
| Q46261727 | Effect of a Lactobacillus Salivarius Probiotic on a Double-Species Streptococcus Mutans and Candida Albicans Caries Biofilm. |
| Q90247983 | Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis |
| Q64388687 | Effects of Probiotic Lactobacillus acidophilus Strain INMIA 9602 Er 317/402 and Putative Probiotic Lactobacilli on DNA Damages in the Small Intestine of Wistar Rats In Vivo |
| Q40101950 | Efficacy and Safety of Saccharomyces boulardii in Acute Rotavirus Diarrhea: Double Blind Randomized Controlled Trial from a Developing Country |
| Q36271872 | Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis |
| Q35919704 | Efficacy of oral Bifidobacterium bifidum ATCC 29521 on microflora and antioxidant in mice. |
| Q36051017 | Evaluation of probiotic potential of yeasts isolated from traditional cheeses manufactured in Serbia and Croatia |
| Q46300594 | Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients |
| Q34286137 | Fighting fire with fire: is it time to use probiotics to manage pathogenic bacterial diseases? |
| Q92219510 | Fungal-Bacterial Interactions in Health and Disease |
| Q55257462 | Genomic and probiotic characterization of SJP-SNU strain of Pichia kudriavzevii. |
| Q42099613 | Gleaning evolutionary insights from the genome sequence of a probiotic yeast Saccharomyces boulardii. |
| Q96306955 | Human microbiome: an academic update on human body site specific surveillance and its possible role |
| Q46372148 | Improved antimicrobial activity of Pediococcus acidilactici against Salmonella Gallinarum by UV mutagenesis and genome shuffling. |
| Q39251357 | Improving health from the inside: Use of engineered intestinal microorganisms as in situ cytokine delivery system |
| Q50166707 | In vivo probiotic and antimicrobial photodynamic therapy as alternative therapies against cryptococcosis are ineffective |
| Q36278070 | Infant fungal communities: current knowledge and research opportunities |
| Q46390353 | Influence of freezing temperatures prior to freeze-drying on viability of yeasts and lactic acid bacteria isolated from wine. |
| Q92032230 | Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives |
| Q47116608 | LC3-Associated Phagocytosis Is Required for Dendritic Cell Inflammatory Cytokine Response to Gut Commensal Yeast Saccharomyces cerevisiae. |
| Q93560961 | Letters to the editor |
| Q58594084 | Mechanism and therapeutic effects of Saccharomyces boulardii on experimental colitis in mice |
| Q40757760 | Modulation of IL-12 and IFNγ by probiotic supplementation promotes protection against Toxocara canis infection in mice |
| Q93164681 | Mycobiome in the Gut: A Multiperspective Review |
| Q35862915 | Novel approaches to treating Clostridium difficile-associated colitis. |
| Q55027467 | Oral Administration of Recombinant Saccharomyces boulardii Expressing Ovalbumin-CPE Fusion Protein Induces Antibody Response in Mice. |
| Q35550821 | Oral administration of Bifidobacterim bifidum for modulating microflora, acid and bile resistance, and physiological indices in mice. |
| Q35256601 | Oral administration of Saccharomyces boulardii ameliorates carbon tetrachloride-induced liver fibrosis in rats via reducing intestinal permeability and modulating gut microbial composition |
| Q52944713 | Patterns in Saccharomyces cerevisiae yeast colonies via magnetic resonance imaging. |
| Q86233578 | PrimiOtic and PrimiOtic Plus: novel probiotic for primates suffering from idiopathic chronic diarrhea |
| Q40579622 | Probiotic Saccharomyces boulardii CNCM I-745 prevents outbreak-associated Clostridium difficile-associated cecal inflammation in hamsters |
| Q40649724 | Probiotic yeast Saccharomyces boulardii (nom. nud.) modulates adhesive properties of Candida glabrata |
| Q26800020 | Probiotic-based strategies for therapeutic and prophylactic use against multiple gastrointestinal diseases |
| Q38081229 | Probiotics and prebiotics in pediatric diarrheal disorders |
| Q30835665 | Probiotics for vaginal health in South Africa: what is on retailers' shelves? |
| Q28087443 | Probiotics, prebiotics and synbiotics- a review |
| Q38689709 | Production and Biomedical Applications of Probiotic Biosurfactants |
| Q26801516 | Review of current methods for characterizing virulence and pathogenicity potential of industrial Saccharomyces cerevisiae strains towards humans |
| Q34583104 | S-Adenosyl-L-methionine protects the probiotic yeast, Saccharomyces boulardii, from acid-induced cell death |
| Q38226331 | Saccharomyces boulardii CNCM I-745 in different clinical conditions |
| Q41502760 | Saccharomyces boulardii CNCM I-745 reduces the duration of diarrhoea, length of emergency care and hospital stay in children with acute diarrhoea |
| Q40113239 | Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS. |
| Q26796416 | Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - a review |
| Q92166707 | Saccharomyces boulardii inhibits the expression of pro-inflammatory cytokines and inducible nitric oxide synthase genes in the colonic mucosa of rats experimentally-infected with Blastocystis subtype-3 cysts |
| Q28236940 | Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum |
| Q57121151 | Screening and characterization of probiotic criteria of and strains |
| Q91905937 | Supplementing a yeast probiotic to pre-weaning Holstein calves: Feed intake, growth and fecal biomarkers of gut health |
| Q88766183 | Survival of Planktonic and Sessile Cells of Lactobacillus rhamnosus and Lactobacillus reuteri upon Exposure to Simulated Fasting-State Gastrointestinal Conditions |
| Q40389822 | Synergistic effects of fenbendazole and metronidazole against Giardia muris in Swiss mice naturally infected |
| Q34487166 | Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea |
| Q90285055 | The Role of Intestinal Fungi and Its Metabolites in Chronic Liver Diseases |
| Q38822566 | The Saccharomyces boulardii CNCM I-745 strain shows protective effects against the B. anthracis LT toxin |
| Q92993814 | The effects of probiotic Saccharomyces boulardii on the mental health, quality of life, fatigue, pain, and indices of inflammation and oxidative stress in patients with multiple sclerosis: study protocol for a double-blind randomized controlled clin |
| Q94543861 | Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view |
Search more.